WHITE PAPER: The Growing Importance of Community Data for Brand Managers & Commercial Teams

This week's BioPharma Dive brought to you by

An estimated 85% of cancer patients in the U.S. are treated in community settings by oncologists managing a broad spectrum of cancer types.¹ For commercial and brand leaders in oncology, community oncology data is not just relevant, it’s essential for driving an informed strategy.

Our white paper, “The growing importance of community data for brand managers and commercial teams”, explores how real-world clinical insights from community practices can help you:

Understand the patient journey in the community setting
Leverage biomarker data to refine brand strategy and stay ahead in a competitive market
Harness the power of physician-level data to understand treatment patterns

Download the white paper to explore how community oncology data can inform your brand strategy.

Download now

[1] Bringing Research to the Community to Reduce Cancer Disparities, National Cancer Institute website. Click Here

Ontada®, 33 Arch Street, Boston, MA 02110, United States of America

Want to reach 108,000+ biopharma executives with your own message? Get the media kit or contact us directly at advertising@industrydive.com.

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466